The RFK Jr Peptide List: What It Means for Research Access
Written by NorthPeptide Research Team | Reviewed February 28, 2026
Written by NorthPeptide Research Team
Ready to explore research-grade peptides?
For laboratory and research use only. Not for human consumption.
Quick summary: In early 2026, Robert F. Kennedy Jr.
In early 2026, Robert F. Kennedy Jr. appeared on Joe Rogan’s podcast (JRE #2461) and did something no other HHS Secretary has done: he named specific peptides he wanted reclassified from the FDA’s Category 2 drug list. For anyone involved in peptide research, it was a remarkable moment.
But the actual implications are complicated. Here’s what he said, what it means, and what’s likely to happen.
What Is Category 2, and Why Does It Matter?
Under FDA regulations, compounding pharmacies can produce custom medications — but only using approved “bulk drug substances.” The FDA maintains categories that determine how these substances can be used:
- Category 1: Approved for compounding with minimal restrictions. These are established drugs with long safety histories.
- Category 2: Under evaluation. These substances are flagged for potential safety concerns, inadequate characterization, or lack of sufficient clinical data. While in Category 2, compounding pharmacies face significant restrictions on producing them.
- Category 3: Denied — deemed too risky for compounding.
The problem: when the FDA moved several popular peptides to Category 2 in 2023-2024, it effectively restricted access for researchers, clinics, and compounding pharmacies that had been working with these compounds — some for decades.
The Full List: 14 Peptides RFK Jr. Named
On the Rogan episode, Kennedy listed these peptides as candidates for removal from Category 2:
| # | Peptide | Primary Research Area | Category 2 Since |
|---|---|---|---|
| 1 | BPC-157 | Tissue repair, gastroprotection | 2023 |
| 2 | Thymosin Alpha-1 | Immune modulation | 2024 |
| 3 | Thymosin Beta-4 (TB-500) | Wound healing, inflammation | 2024 |
| 4 | KPV | Anti-inflammatory (gut) | 2024 |
| 5 | GHK-Cu | Skin repair, anti-aging | 2024 |
| 6 | Epithalon | Telomerase activation | 2024 |
| 7 | Selank | Anxiolytic, nootropic | 2024 |
| 8 | Semax | Neuroprotection, cognition | 2024 |
| 9 | DSIP | Sleep regulation | 2024 |
| 10 | Dihexa | Cognitive enhancement | 2024 |
| 11 | SS-31 (Elamipretide) | Mitochondrial function | 2024 |
| 12 | MOTS-c | Metabolic function | 2024 |
| 13 | Cerebrolysin | Neurotrophic support | 2024 |
| 14 | PT-141 (Bremelanotide) | Sexual dysfunction | 2024 |
He also mentioned five additional compounds as being “under review” by his team, including AOD-9604, CJC-1295, Ipamorelin, Tesamorelin, and GHRP-6.
Why This Matters for Research
The Category 2 designation doesn’t just affect clinics — it affects the entire research supply chain:
- Compounding pharmacies that produced research-grade peptides have stopped or restricted production
- Research suppliers face uncertainty about which compounds they can legally sell and in what form
- Ongoing studies that relied on compounded peptides may face supply disruptions
- Pricing for remaining available peptides has increased as supply contracted
For compounds like BPC-157 — which has over 1,000 published papers but no FDA-approved form — the Category 2 designation created a catch-22: the FDA wants more clinical data before approving compounding, but the compounding restriction makes it harder to generate that data.
What Would Reclassification Actually Look Like?
Kennedy’s statements are significant because the HHS Secretary has authority over the FDA, but the process isn’t as simple as announcing a decision on a podcast. Here’s what would likely need to happen:
- FDA internal review: The agency’s Pharmacy Compounding Advisory Committee would need to re-evaluate each substance’s safety profile
- Public comment period: Federal rulemaking requires opportunity for public input — this typically takes 60-90 days
- Final rule publication: Changes would need to be published in the Federal Register
- Implementation: State pharmacy boards would need to update their own regulations to align
Optimistic timeline: 6-12 months for the first compounds. Realistic timeline: 12-24 months, and likely not all 14 at once. Some compounds (BPC-157, Thymosin Alpha-1) have stronger safety dossiers and could move faster. Others (Dihexa, DSIP) have thinner safety data and may face more scrutiny.
The Political Reality
It’s worth noting the political dynamics at play. Kennedy’s stance on peptides aligns with a broader deregulatory agenda, and peptide access has become something of a cultural issue in the health-freedom and biohacking communities. The Joe Rogan appearance was almost certainly strategic — reaching millions of listeners who are already interested in these compounds.
But political will and regulatory process don’t always move at the same speed. The FDA career staff who would actually process these reclassifications may not share the urgency. And pharmaceutical companies that have invested in developing some of these compounds (like Bremelanotide/PT-141, which is FDA-approved as Vyleesi) may lobby against broad compounding access.
What About the SAFE Act?
Running parallel to the executive branch action is the SAFE Act (S. 3794 / H.R. 6509) — congressional legislation that would create a more systematic framework for peptide regulation. Key provisions include:
- Establishing clear criteria for evaluating peptide safety for compounding
- Creating an expedited review pathway for peptides with established safety histories
- Requiring the FDA to consider published research evidence, not just formal clinical trials
- Protecting researcher access to compounds for legitimate scientific use
If both the executive action (Kennedy’s reclassification push) and the legislative action (SAFE Act) move forward, the combined effect could significantly change the regulatory landscape for peptide research in the US.
Read more: The SAFE Act and Peptide Research →
What Researchers Should Do Now
For those actively conducting peptide research, the practical advice is:
- Stay current on regulatory changes — follow the FDA’s Compounding page and relevant trade organizations
- Document your research applications — if reclassification happens, having clear documentation of legitimate research use will matter
- Source from reputable suppliers — quality and purity matter more than ever when regulatory scrutiny is high
- Follow the comment periods — when the FDA opens public comment on specific peptides, researcher input carries weight
The Bottom Line
Kennedy’s Rogan appearance marked the first time a cabinet-level official publicly advocated for specific peptide reclassification. Whether it translates to actual regulatory change depends on the messy reality of federal agencies, pharmaceutical lobbying, and political priorities. But for the first time in several years, the trajectory appears to be moving toward expanded access rather than further restriction.
Related Research
- RFK Jr on Joe Rogan: Full Peptide List & Analysis
- The SAFE Act and Peptide Research: What You Need to Know
- BPC-157 Research Guide
- Thymosin Alpha-1 Research Guide
Products mentioned in this article:
Summary of Key Research References
| Study | Year | Type | Focus | Reference |
|---|---|---|---|---|
| Bays et al. | 2024 | Position Statement | Obesity Medicine Association FAQs on compounded peptides | PMC11369382 |
| Elsayed et al. | 2025 | Review | Regulatory guidelines for therapeutic peptide and protein analysis | PMC11806371 |
| Sood et al. | 2025 | Commentary | Global rise of compounded weight-loss medicines: risks and trends | PMC12164287 |
| Al Shaer et al. | 2024 | Review | 2023 FDA TIDES peptide and oligonucleotide approvals | PMC10893093 |
| Al Musaimi et al. | 2024 | Review | FDA-approved natural and engineered peptide analogues in GLP-1, GIP, and related families | PMC10968328 |
| McGuire et al. | 2025 | Narrative Review | BPC-157 for musculoskeletal healing and regulatory status | PMC12446177 |
| Vasireddi et al. | 2025 | Systematic Review | BPC-157 in orthopaedic sports medicine and FDA Category 2 classification | PMC12313605 |
All products mentioned are sold strictly for laboratory and research use. Not for human consumption.